250 results on '"Jiang, Hao"'
Search Results
2. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide
3. Interferon-α-2b As a Maintenance Therapy Gain a High Rate of MRD Negative Conversion and Improve RFS in Patients with Favorable-Risk Acute Myeloid Leukemia----a Prospective, Single-Arm Study
4. Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome
5. Outcome and Molecular Measurable Residual Disease Monitoring in Adult B-Cell Acute Lymphoblastic Leukemia Patients with MEF2D Fusions
6. A Novel Risk Stratification Model for Cytogenetically Normal Acute Myeloid Leukemia withFLT3-ITDMutation
7. The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells
8. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial
9. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission
10. Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
11. A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion
12. Safety and Short-Term Efficacy of Venetoclax Combined with Azacitidine in Acute Myeloid Leukemia: A Single Institution Experience
13. The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study
14. Detection of CSRP2 Transcript Levels By Real-Time Quantitative PCR May be a Useful Tool for Monitoring Minimal Residual Disease in B-Cell ALL
15. All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP
16. Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET 020)
17. Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia
18. Only FLT3-ITD Mutation Did Not Have a Deleterious Effect on Acute Myeloid Leukemia Patients with NPM1 Mutation, but Concomitant with DNMT3A Mutation or a＜3log Reduction of MRD2 Predicted Poor Survival
19. A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy
20. Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia
21. Anti-PD-1 Antibody (Sintilimab) Plus Decitabine As First Line Treatment for Patients with Higher-Risk Myelodysplastic Syndrome (MDS): Primary Results from a Single-Arm,Open-Label,Phase II Study
22. Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes
23. Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia
24. A Novel Risk Stratification Model for Cytogenetically Normal Acute Myeloid Leukemia with FLT3-ITD Mutation
25. Dead/H-Box Helicase 11 (DDX11) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice
26. Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3-itd Mutation
27. Detection of Measurable Residual Disease May Better Predict the Outcome Rather Than Mutations Based on Next-Generation Sequencing in Acute Myeloid Leukemia with Biallelic Mutations of CEBPA
28. Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia
29. Outcome of Standard Immunosuppressive Therapy with or without Eltrombopag for Chinese Patients with Severe Aplastic Anemia in the Real World
30. The Lost or Absence of MRD<0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis
31. Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML
32. All-transretinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP
33. FINAL Results of an Phase, Multicenter, Randomied, Controlled OPEN LEVEL Trial: Decitabine Therapy in Patients with Myelodysplastic Syndromes
34. Clonal Trajectories in Persons with Acute Myeloid Leukemia and Normal Cytogenetics Relapsing after Intensive Chemotherapy and after Allotransplants. Does Pretransplant Conditioning Contribute to Mutation Topography?
35. Interferon May Help Control the Recurrence of Chronic Myeloid Leukemia after Discontinuation of Tyrosine Kinase Inhibitor
36. Recombinant Human Thrombopoietin Increases Platelet Numbers and Reduces the Risk of Bleeding Events in Thrombocytopenic Patients with Chronic Hepatitis B Virus Infection: A Multicenter Observational Study
37. Osteoclast Stimulatory Transmembrane Protein (OCSTAMP) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma
38. Control of Hematopoietic Stem Cell Function through Epigenetic Regulation of Energy Metabolism and Genome Integrity
39. Regulation of Fetal Liver Hematopoietic Stem Cell Function By the Dpy30 Subunit of Set1/Mll Complexes
40. ADAM28 Enhanced the Growth and Dissemination of AML and Identified a Subgroup of AML Patients with a High Risk of Relapse in a Prospective Clinical Study
41. Aberrant TNFAIP3 Induces Mesenchymal Stem Cell Impairment Via the NF-Kb/SMAD7 Signaling Pathway in Immune Thrombocytopenia
42. Janus Kinase Inhibition By Ruxolitinib Combined with Nilotinib Has Superior Anti-Leukemia Propagating Cells Effect in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
43. C-KIT- Mutated t(8;21)AML Patients with >3log Reduction of MRD Conferred a Very High Relapse and Need HSCT to Improve Outcome
44. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: To Allogeneic Stem Cell Transplantation or Not? a Single Center Experience
45. The Initial Level of MLL-PTD Affects the Prognosis of Patients with Acute Myeloid Leukemia
46. Structural and Functional Characterization of a Codon Optimized Coagulation Factor VIII
47. Role of the Dpy30 Subunit of Set1/Mll Complexes in Lymphomagenesis through Epigenetic Regulation of Myc Activity
48. Varying Responses of PML-Rara with Different Genetic Mutations to Arsenic Trioxide
49. The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy
50. Constitutively active ezrin increases membrane tension, slows migration, and impedes endothelial transmigration of lymphocytes in vivo in mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.